Literature DB >> 18608092

Scrutinizing enrollment in ALS clinical trials: room for improvement?

Richard S Bedlack1, Daniel M Pastula, Emily Welsh, Darlene Pulley, Merit E Cudkowicz.   

Abstract

Enrollment in ALS trials has not been systematically studied. We surveyed the ALS Research Group (ALSRG) to learn their impressions of enrollment at ALS clinics across North America. We also reviewed completed ALS trials to determine an enrollment rate (subjects per site per month), its variability across trials, whether it is changing over time, and whether it is influenced by 'trial factors'. ALSRG members were polled via an online survey. ALS trials were identified by literature review and investigator contact. Enrollment rate versus publication year was plotted for each trial. Models were created to examine how 'trial factors' were associated with enrollment rate. By survey, percent enrollment is 25% and highly variable (range 0-75%). By literature review, enrollment rate is 2.2 participants/site/month and highly variable (range 0.1-7.5). Enrollment is not improving over time; no 'trial factor' explains the variability in enrollment across trials. Behaviors among clinic directors and patients were identified that may influence enrollment. In conclusion, ALS trial enrollment rate is low, highly variable and not influenced by trial design factors. 'Patient factors' and 'physician factors' may play more important roles in influencing enrollment, as in oncology trials. Our survey data support this idea, and provide potential mechanisms for improving enrollment.

Entities:  

Mesh:

Year:  2008        PMID: 18608092     DOI: 10.1080/17482960802195913

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  12 in total

Review 1.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

2.  Depression in amyotrophic lateral sclerosis.

Authors:  Nazem Atassi; Amanda Cook; Cristiana M E Pineda; Padmaja Yerramilli-Rao; Darlene Pulley; Merit Cudkowicz
Journal:  Amyotroph Lateral Scler       Date:  2010-11-24

3.  Modeling the course of amyotrophic lateral sclerosis.

Authors:  Christina Fournier; Jonathan D Glass
Journal:  Nat Biotechnol       Date:  2015-01       Impact factor: 54.908

4.  ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Authors:  Hiroshi Mitsumoto; Pam Factor-Litvak; Howard Andrews; Raymond R Goetz; Leslie Andrews; Judith G Rabkin; Martin McElhiney; Jeri Nieves; Regina M Santella; Jennifer Murphy; Jonathan Hupf; Jess Singleton; David Merle; Mary Kilty; Daragh Heitzman; Richard S Bedlack; Robert G Miller; Jonathan S Katz; Dallas Forshew; Richard J Barohn; Eric J Sorenson; Bjorn Oskarsson; J Americo M Fernandes Filho; Edward J Kasarskis; Catherine Lomen-Hoerth; Tahseen Mozaffar; Yvonne D Rollins; Sharon P Nations; Andrea J Swenson; Jeremy M Shefner; Jinsy A Andrews; Boguslawa A Koczon-Jaremko
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-02-24       Impact factor: 4.092

5.  The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Michael E Bozik; Evan W Ingersoll; Robert Miller; Hiroshi Mitsumoto; Jeremy Shefner; Dan H Moore; David Schoenfeld; James L Mather; Donald Archibald; Mary Sullivan; Craig Amburgey; Juliet Moritz; Valentin K Gribkoff
Journal:  Nat Med       Date:  2011-11-20       Impact factor: 53.440

6.  Harnessing the power of the electronic health record for ALS research and quality improvement: CReATe CAPTURE-ALS and the ALS Toolkit.

Authors:  Volkan Granit; Anne-Laure Grignon; Joanne Wuu; Jonathan Katz; David Walk; Sumaira Hussain; Jessica Hernandez; Carlayne Jackson; James Caress; Tom Yosick; Nancy Smider; Michael Benatar
Journal:  Muscle Nerve       Date:  2021-11-16       Impact factor: 3.217

7.  Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.

Authors:  Merit Cudkowicz; Marianne K Chase; Christopher S Coffey; Dixie J Ecklund; Brenda J Thornell; Codrin Lungu; Katy Mahoney; Laurie Gutmann; Jeremy M Shefner; Kevin J Staley; Michael Bosch; Eric Foster; Jeffrey D Long; Emine O Bayman; James Torner; Jon Yankey; Richard Peters; Trevis Huff; Robin A Conwit; Shlomo Shinnar; Donna Patch; Basil T Darras; Audrey Ellis; Roger J Packer; Karen S Marder; Claudia A Chiriboga; Claire Henchcliffe; Joyce Ann Moran; Blagovest Nikolov; Stewart A Factor; Carole Seeley; Steven M Greenberg; Anthony A Amato; Sara DeGregorio; Tanya Simuni; Tina Ward; John T Kissel; Stephen J Kolb; Amy Bartlett; Joseph F Quinn; Kellie Keith; Steven R Levine; Nadege Gilles; Patricia K Coyle; Jessica Lamb; Gil I Wolfe; Annemarie Crumlish; Luis Mejico; Muhammad Maaz Iqbal; James D Bowen; Caryl Tongco; Louis B Nabors; Khurram Bashir; Melanie Benge; Craig M McDonald; Erik K Henricson; Björn Oskarsson; Bruce H Dobkin; Catherine Canamar; Tracy A Glauser; Daniel Woo; Angela Molloy; Peggy Clark; Timothy L Vollmer; Alexander J Stein; Richard J Barohn; Mazen M Dimachkie; Jean-Baptiste Le Pichon; Michael G Benatar; Julie Steele; Lawrence Wechsler; Paula R Clemens; Christine Amity; Robert G Holloway; Christine Annis; Mark P Goldberg; Mariam Andersen; Susan T Iannaccone; A Gordon Smith; J Robinson Singleton; Mariana Doudova; E Clarke Haley; Mark S Quigg; Stephanie Lowenhaupt; Beth A Malow; Karen Adkins; David B Clifford; Mengesha A Teshome; Noreen Connolly
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

8.  Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study.

Authors:  Ruben P A van Eijk; Jaap N E Bakers; Tommy M Bunte; Arianne J de Fockert; Marinus J C Eijkemans; Leonard H van den Berg
Journal:  J Neurol       Date:  2019-06-11       Impact factor: 4.849

9.  Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol.

Authors:  Emily Beswick; Stella A Glasmacher; Rachel Dakin; Judith Newton; Alan Carson; Sharon Abrahams; Siddharthan Chandran; Suvankar Pal
Journal:  BMJ Open       Date:  2021-03-23       Impact factor: 2.692

10.  Neuromuscular Diseases Care in the Era of COVID-19.

Authors:  Bernat Bertran Recasens; Miguel Angel Rubio
Journal:  Front Neurol       Date:  2020-11-26       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.